FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/04/2026
Voltar para busca
Dado oficial do USPTO
NORDICPRO-C2
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
NORDICPRO-C2
ST13
US500000079380013Classe
5, 42
Pedido
79380013
Registro
7933247
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
10/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
19/07/2023
Data de registro
09/09/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/09/2025
Última transação
10/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DK
Examinador
BIBB, SCOTT
Unidade examinadora
L90
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Nordic Bioscience A/S
Representantes
Andrew M. Smith Resonate IP, LLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
diagnostic biomarker reagents for medical and clinical purposes; diagnostic biomarkers for use individually or in combination to detect tissue formationtissue remodelingtissue destruction; diagnostic biomarker assays to identify disease activity; medical diagnostic biomarker assays to quantify disease activity; medical diagnostic biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detectiondisease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; medical diagnostic test strips for research and diagnostic use for protein fragment detectiondisease detectiondisease analysis and quantifying disease activity; diagnostic preparations for medical purposes; diagnostic agents for medical use
Classe 42
custom design and development of blood-based biomarker assays to identifyquantify and analyse disease activity; custom design and development of diagnostic biomarker reagents for medicalpharmaceuticalscientific purposes; custom design and development of biochemicalpharmaceuticalmedical assays; custom design and development of biomarkers for use individually or in combination to detect tissue formationtissue remodelingtissue destruction; providing scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; medical and scientific researchidentification of predictive and prognostic biomarkers for clinical trials; medical and scientific researchidentifying patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services for clinical trials; scientific research in the nature of conducting clinical trials for others; biological research and analysisanalysis of pharmacodynamic data; biological research and analysisanalysis of data relating to biomarkers; development services in the field of diagnostic preparationsequipment and tests; medical and scientific researchconducting clinical testing services for others; providing reagent sample testing and diagnostic services for others for scientific research purposes namely diagnostic testing services; medical research laboratory services; research laboratory services in the fields of medical and pharmaceutical research; adviceinformation and assistance relating to the foregoing
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/03/2026
FIMP
FINAL DISPOSITION PROCESSED
24/03/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/12/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/09/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
09/09/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
22/07/2025
PUBO
PUBLISHED FOR OPPOSITION
22/07/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16/07/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/06/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
17/06/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
17/06/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
17/06/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
17/06/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
22/03/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/03/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/03/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/11/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/11/2024
RFNT
REFUSAL PROCESSED BY IB
27/05/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/05/2024
RFRR
REFUSAL PROCESSED BY MPU
08/05/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/05/2024
CNRT
NON-FINAL ACTION WRITTEN
02/05/2024
DOCK
ASSIGNED TO EXAMINER
25/03/2024
MAFR
APPLICATION FILING RECEIPT MAILED
10/10/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/10/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/10/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NORDICPRO-C2 ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.